AU2018254884C1 - Blood purification through alkalifying agent - Google Patents

Blood purification through alkalifying agent Download PDF

Info

Publication number
AU2018254884C1
AU2018254884C1 AU2018254884A AU2018254884A AU2018254884C1 AU 2018254884 C1 AU2018254884 C1 AU 2018254884C1 AU 2018254884 A AU2018254884 A AU 2018254884A AU 2018254884 A AU2018254884 A AU 2018254884A AU 2018254884 C1 AU2018254884 C1 AU 2018254884C1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
alkalinizing agent
concentration
administration
urine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018254884A
Other languages
English (en)
Other versions
AU2018254884B2 (en
AU2018254884A1 (en
Inventor
Michiaki Abe
Kazuhiko Kawaguchi
Seizo Koshiba
Koichiro Nishioka
Yasuyuki Teranaka
Satomi Yamasaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tohoku University NUC
Nippon Chemiphar Co Ltd
Original Assignee
Tohoku University NUC
Nippon Chemiphar Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2017085741A external-priority patent/JP7578234B2/ja
Priority claimed from PCT/JP2017/032931 external-priority patent/WO2018193648A1/ja
Application filed by Tohoku University NUC, Nippon Chemiphar Co Ltd filed Critical Tohoku University NUC
Publication of AU2018254884A1 publication Critical patent/AU2018254884A1/en
Application granted granted Critical
Publication of AU2018254884B2 publication Critical patent/AU2018254884B2/en
Publication of AU2018254884C1 publication Critical patent/AU2018254884C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2018254884A 2017-04-18 2018-03-13 Blood purification through alkalifying agent Active AU2018254884C1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP2017-082423 2017-04-18
JP2017082423 2017-04-18
JP2017-085741 2017-04-24
JP2017085741A JP7578234B2 (ja) 2017-04-18 2017-04-24 アルカリ性化剤による血液浄化
JP2017-103935 2017-05-25
JP2017103935 2017-05-25
AUPCT/JP2017/032931 2017-09-12
PCT/JP2017/032931 WO2018193648A1 (ja) 2017-04-18 2017-09-12 アルカリ性化剤による血液浄化
PCT/JP2018/009679 WO2018193752A1 (ja) 2017-04-18 2018-03-13 アルカリ性化剤による血液浄化

Publications (3)

Publication Number Publication Date
AU2018254884A1 AU2018254884A1 (en) 2019-11-07
AU2018254884B2 AU2018254884B2 (en) 2023-12-14
AU2018254884C1 true AU2018254884C1 (en) 2024-04-11

Family

ID=65033758

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018254884A Active AU2018254884C1 (en) 2017-04-18 2018-03-13 Blood purification through alkalifying agent

Country Status (8)

Country Link
US (1) US20210121426A1 (https=)
EP (1) EP3616721B1 (https=)
JP (3) JP7219898B2 (https=)
KR (1) KR102685723B1 (https=)
CN (1) CN110799214A (https=)
AU (1) AU2018254884C1 (https=)
CA (1) CA3060154A1 (https=)
TW (1) TWI813560B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210196747A1 (en) * 2018-05-25 2021-07-01 University Of The Ryukyus Metabolism improving agent
EP3868371A4 (en) 2018-10-17 2022-11-02 Tohoku University Novel pharmaceutical composition
BR112022018917A2 (pt) * 2020-03-26 2022-12-13 Univ Tohoku Agente protetor da função renal
CN114794346A (zh) * 2022-04-25 2022-07-29 武汉汇天诚科技有限公司 一种复合固体饮料的配方

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60105619A (ja) * 1983-11-15 1985-06-11 Nippon Chemiphar Co Ltd 尿アルカリ化性食品組成物
JP4087929B2 (ja) * 1997-08-27 2008-05-21 日清ペットフード株式会社 猫慢性腎不全治療用組成物及びその治療方法
JP2004131406A (ja) 2002-10-09 2004-04-30 Sekisui Chem Co Ltd 尿毒症性物質特異的認識ポリマー及び経口吸着剤
EP3066923B1 (en) 2006-01-30 2025-11-05 Panion & BF Biotech Inc. Method of treating chronic kidney disease
JP2007217366A (ja) 2006-02-17 2007-08-30 Kirin Brewery Co Ltd 尿酸値降下用組成物
US20100266712A1 (en) * 2007-05-24 2010-10-21 Austin Health Prevention of Acute Kidney Injury
BRPI0816066A2 (pt) * 2007-08-31 2017-05-02 C B Fleet Company Incorporated método de prevenção de nefrocalcinose
JP5197846B2 (ja) * 2009-04-30 2013-05-15 紀陽 田仲 腎疾患重篤度を判定する方法又は装置若しくはその作動方法
JP6164719B2 (ja) 2009-10-27 2017-07-19 エイワイファーマ株式会社 白金含有薬剤投与による腎障害の軽減剤
CN105671120B (zh) 2010-07-05 2019-02-19 株式会社明治 具有肠内腐败物质的减少作用的双歧杆菌
MX357998B (es) * 2015-03-20 2018-07-11 Antonio Hernandez Miramontes Jorge Una mezcla de acidos carboxilicos, especificamente acido citrico, acido succinico, acido fumarico y acido malico para el tratamiento de pacientes con insuficiencia renal cronica, insuficiencia renal aguda, hepatopatias agudas o cronicas que cursen con hiperamonemia, enfermedades congenitas con alteraciones enzimaticas en el ciclo de la urea, asi como condiciones clínicas que cursen con balance nitrogenado negativo.
JP6490614B2 (ja) * 2015-03-30 2019-03-27 景博 内田 インドキシル硫酸の測定方法
EP3868371A4 (en) * 2018-10-17 2022-11-02 Tohoku University Novel pharmaceutical composition
US20210393562A1 (en) * 2018-10-17 2021-12-23 Nippon Chemiphar Co., Ltd. Therapeutic or prophylactic agent for nocturnal polyuria
US20220202752A1 (en) * 2019-04-28 2022-06-30 Tohoku University Novel pharmaceutical composition

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ASHUTOSH MAHAJAN et al. KIDNEY INTERNATIONAL (2010) vol. 78, no. 3, pages 303-309 *
GADOLA LILIANA et al. KIDNEY INTERNATIONAL (2004) vol. 65, no. 4, pages 1224-1230 *
GEORGE A TANNER et al. J. AM. SOC. NEPHROL. (1998) vol. 9, pages 1242-1248 *
IONE DE BRITO-ASHURST et al. "Bicarbonate Supplementation Slows Progression of CKD and Improves Nutritional Status", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009) vol. 20, no. 9, pages 2075-2084 *
NIMRIT GORAYA et al. KIDNEY INTERNATIONAL (2012) vol. 81, no. 1, pages 86-93 *
Pernix Manufacturing "Material Safety Data Sheet Cytra-3 Syrup" Dated 4 September 2013. Retrieved from the internet on 8 May 2023 <URL: https://imgcdn.mckesson.com/CumulusWeb/Click_and_learn/MSDS_9CYPRS_CYTRA_3_SOL.pdf> *
SOROT PHISITKUL et al. "Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR", KIDNEY INTERNATIONAL (2010) vol. 77, no. 7, pages 617 - 623 *
SOUMA, T. et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011) vol. 22, no. 4, pages 635-648 *

Also Published As

Publication number Publication date
JPWO2018193752A1 (ja) 2020-03-05
CN110799214A (zh) 2020-02-14
CA3060154A1 (en) 2018-10-25
JP7756863B2 (ja) 2025-10-21
US20210121426A1 (en) 2021-04-29
AU2018254884B2 (en) 2023-12-14
EP3616721C0 (en) 2024-12-04
KR20190137147A (ko) 2019-12-10
TW201838684A (zh) 2018-11-01
EP3616721A4 (en) 2020-12-30
JPWO2018193648A1 (ja) 2020-02-27
AU2018254884A1 (en) 2019-11-07
TWI813560B (zh) 2023-09-01
EP3616721A1 (en) 2020-03-04
JP2023115271A (ja) 2023-08-18
JP7219898B2 (ja) 2023-02-09
EP3616721B1 (en) 2024-12-04
KR102685723B1 (ko) 2024-07-16

Similar Documents

Publication Publication Date Title
TWI847827B (zh) 利用鹼性化劑的血液淨化
AU2018254884C1 (en) Blood purification through alkalifying agent
JP5479318B2 (ja) アログリプチンおよび塩酸メトホルミンを含有する固形製剤
JP5284967B2 (ja) 打錠障害を生じない錠剤製剤
CN112955130A (zh) 包含取代茚满的固体分散体和药物组合物及其制备和使用方法
KR20230057388A (ko) Sglt-2 억제제와 안지오텐신 수용체 길항제의 조성물 및 이의 용도
CN101966181A (zh) 包含坎地沙坦和氨氯地平的口服固体制剂及其新应用
JP2026063342A (ja) 腎機能保護剤
EP3868370A1 (en) Therapeutic or prophylactic agent for nocturia
KR20170012169A (ko) 경구용 복합제제
US20210244731A1 (en) Tablet containing antitumor agent
EP3229841A1 (en) Veterinary composition comprising torasemide for the treatment of pulmonary edema associated with heart failure in domestic animals
US12048677B2 (en) Compositions and uses thereof for the treatment of heart failure in domestic animals
KR20210152943A (ko) 암로디핀, 로사르탄 및 클로르탈리돈을 단층정에 포함하는 심혈관계 질환의 예방 또는 치료용 약제학적 복합제제
HK40079287A (en) Renal function protectant
JP2021024803A (ja) クエン酸第二鉄水和物を含む固形製剤
CN109069438A (zh) 包含β阻滞剂、转化酶抑制剂和抗高血压药或NSAID的药物组合物
CN107088195A (zh) 一种治疗糖尿病肾病的药物组合物

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 DEC 2023

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 DEC 2023

FGA Letters patent sealed or granted (standard patent)